TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8864322
Drug: Ganglion blocking
Normalized name: Ganglion blocking agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganglion blocking drug pentolinium (5 mg) with TRH 500 micrograms
Study: 8864322
Drug: Alpha-adrenoceptor blockade
Normalized name: One-Alpha
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-adrenoceptor blockade with thymoxamine (0.3 mg kg-1 bolus + 0.3 mg kg-1 h-1 infusion) with TRH 500 micrograms
Study: 8864322
Drug: Intravenous propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous propranolol (10 mg i.v. over 10 min) with TRH 500 micrograms
Study: 25840580
Drug: Carperitide infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carperitide infusion
Study: 20825986
Drug: Celiprolol (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol (up to 400 mg per day, administered twice daily, titrated by 100 mg every 6 months)
Study: 16855464
Drug: Sildenafil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (50 mg up to 100 mg per usage)
Study: 11061616
Drug: Increasing GM-CSF
Normalized name: axatilimab-csfr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing GM-CSF doses
Study: 9311404
Drug: Lidocaine (2‐min
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (2‐min bolus, 100 mg; 15 min infusion, 40 micrograms.kg‐1.min‐1)
Study: 2947606
Drug: Hydroxyethylrutosides (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyethylrutosides (600 mg, four times before smoking)
Study: 27507627
Drug: Buccal infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal infiltration of 0.7 mL 8.4% sodium bicarbonate with 0.3 mL 2% lidocaine containing 1:80,000 epinephrine
Study: 27507627
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received 0.7 mL sterile distilled water with 0.3 mL 2% lidocaine containing 1:80,000 epinephrine
Study: 24907722
Drug: Continuous erythropoietin
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous erythropoietin receptor activator (34 patients)
Study: 22540433
Drug: Tramadol (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (600 mg/day)
Study: 10821988
Drug: Methadone (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone (60 mg/day)
Study: 20299774
Drug: Lidocaine suppository
Normalized name: lidocaine Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine suppository (60 mg or 120 mg) + PNB
Study: 20299774
Drug: Lidocaine gel
Normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine gel (10 ml of 2% lidocaine) + PNB
Study: 20299774
Drug: Placebo suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo suppository + PNB
Study: 19317172
Drug: Symptomatic Western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic Western medical therapy (Control)
Study: 12912714
Drug: Amoxicillin-clavulanate (875
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanate (875 mg amoxicillin and 125 mg clavulanic acid, twice daily for 6 days)
Study: 8618198
Drug: Chloral hydrate
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloral hydrate (75 mg/kg administered orally)
Study: 8618198
Drug: Midazolam (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.2 mg/kg administered intravenously)
Study: 2006346
Drug: Balanced anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced anesthesia (isoflurane plus fentanyl) with systemic analgesia on request (piritramide i.m., tramadol, or a simple analgesic).
Study: 6756262
Drug: High-dosage Vitamin
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dosage Vitamin E treatment (target serum E levels, 5-6 mg/dl)
Study: 6756262
Drug: Non-Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-Vitamin E treatment (control group)
Study: 6756262
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E treatment from birth (pilot studies, target serum E levels, 1.5 and 3.0 mg/dl)
Study: 6756262
Drug: Prestudy infants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prestudy infants (1968-72) fed early iron supplements and given formulas with low E:PUFA ratios
Study: 23797459
Drug: Smooth Pursuit
Normalized name: Derma-Smoothe FS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smooth Pursuit Therapy (SPT)
Study: 23797459
Drug: Visual Scanning
Normalized name: chlorpheniramine tannate Oral Tablet [Ed Chlor Tan]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visual Scanning Therapy (VST)
Study: 20979013
Drug: Intravenous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tranexamic acid (TA) 1 g/10 mL in 20 mL of 5% glucose
Study: 20979013
Drug: Placebo (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (30 mL 5% glucose)
Study: 23023559
Drug: Intravenous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tranexamic acid (TA)
Study: 17587398
Drug: Repaglinide 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide 1.0 mg three times daily (t.i.d.)
Study: 17587398
Drug: Nateglinide 90
Normalized name: nateglinide 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide 90 mg three times daily (t.i.d.)
Study: 12698086
Drug: Steroid-free immunosuppression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-free immunosuppression (no steroids)
Study: 12698086
Drug: Steroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid treatment (long-term and short-term)
Study: 10936117
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 500 microg once daily (qd)
Study: 10936117
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 250 microg twice daily (bid)
Study: 10936117
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (both regimens) during 54 weeks of open-label treatment
Study: 1560164
Drug: 50 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 micrograms of inhaled salmeterol
Study: 1560164
Drug: 100 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 micrograms of inhaled salmeterol
Study: 1560164
Drug: 200 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 micrograms of inhaled salbutamol
Study: 2411079
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg acetylsalicylic acid daily for 24 weeks
Study: 25808103
Drug: Placebo daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily for 24 weeks
Study: 25348013
Drug: Total Worker
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Worker Health™ program, implemented through monthly 2-hour peer-led meetings.
Study: 22964967
Drug: Estrogen (17β‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen (17β‐estradiol 1 mg)
Study: 19921145
Drug: Physiotherapeutic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapeutic group training including gait and balance exercises with function‐orientated strengthening (twice weekly over 12 weeks)
Study: 12068250
Drug: Ethanol (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.8 g/kg in juice)
Study: 8559203
Drug: Ragweed-extract immunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ragweed-extract immunotherapy
Study: 30256061
Drug: Taxane-based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxane-based chemotherapy (4 to 6 cycles)
Study: 30256061
Drug: Anthracycline-based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthracycline-based chemotherapy (4 to 6 cycles)
Study: 28811009
Drug: Sugammadex group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex group (Group S) received rocuronium 0.6 mg/kg at anesthesia induction and sugammadex 2 mg/kg at skin incision.
Study: 26054147
Drug: Acupuncture drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture drug anesthesia (ADA)
Study: 24122908
Drug: TRV130 (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRV130 (0.15 to 7 mg administered intravenously over 1 hour)
Study: 24122908
Drug: TRV130 (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRV130 (1.5 mg administered as 30, 15, 5, and 1 minute infusions)
Study: 24122908
Drug: TRV130 (2.2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRV130 (2.2, 4, and 7 mg doses)
Study: 24122908
Drug: TRV130 (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRV130 (7 mg dose)
Study: 21766228
Drug: Placebo (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (500 mg starch/day)
Study: 19156563
Drug: Self-administered psychotherapeutic
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered psychotherapeutic tool
Study: 17971137
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) rehydration
Study: 15135261
Drug: 15 ml
Normalized name: ethanol 0.15 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 ml of linseed oil (rich in ALA) per day (n=60)
Study: 15135261
Drug: 15 ml
Normalized name: ethanol 0.15 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 ml of safflower oil (rich in LA) per day (n=30)
Study: 9610754
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) replacement therapy, mean dose 0.23 ± 0.01 IU/kg/week, divided into daily subcutaneous injections, for 3 years.
Study: 8021731
Drug: Doxorubicin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin alone (60 mg/m2 i.v. every 3 weeks for eight courses)
Study: 8021731
Drug: Doxorubicin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin plus cyclophosphamide (500 mg/m2 i.v. every 3 weeks for eight courses)
Study: 2510460
Drug: Stepwise increased
Normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Stepwise increased hMG dosage (group 1)
Study: 2510460
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose hMG for 2 days followed by constant daily dose (group 2)
Study: 113803
Drug: Zimelidine 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zimelidine 200 mg/day
Study: 4923928
Drug: Amitriptyline 150
Normalized name: amitriptyline 150 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 150 mg/day
Study: 21965226
Drug: Roflumilast 500
Normalized name: ROFLUMILAST 500MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roflumilast 500 μg once daily for 12 weeks
Study: 31354255
Drug: Roflumilast 250
Normalized name: ROFLUMILAST 250MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roflumilast 250 μg once daily for 4 weeks, then 500 μg for 12 weeks (dose-escalation)
Study: 25588782
Drug: Probiotic yogurt
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic yogurt containing Lactobacillus rhamnosus GG, Bifidobacterium lactis, and Lactobacillus acidophilus, 200 g/day
Study: 22185725
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray at 200 μg once daily for 12 weeks
Study: 22185725
Drug: Clarithromycin tablet
Normalized name: Clarithromycin Tablets
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin tablet at 250 mg once daily for 12 weeks
Study: 19523618
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist multiple‐dose protocol (MDP) with OCP pretreatment
Study: 19523618
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist low‐dose long protocol (LP)
Study: 12808614
Drug: Neoral cyclosporin
Normalized name: cyclosporine Oral Capsule [Neoral]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoral cyclosporin (15 mg per kg per day)
Study: 12808614
Drug: Tacrolimus (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus (0.2 mg per kg per day)
Study: 1294894
Drug: Diazepam (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (15 mg)
Study: 8560050
Drug: Lidocaine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1.5 mg/kg intravenous 1 min before EIT)
Study: 1911017
Drug: Cisapride and
Normalized name: Cisapride
DrugBank: Cisapride (DB00604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisapride and ranitidine administered simultaneously
Study: 26402730
Drug: Conjugated Linoleic
Normalized name: CONJUGATED LINOLEIC ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated Linoleic Acid (CLA) 3.2 g/day
Study: 26402730
Drug: Placebo (Olive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Olive oil 4 g/day)
Study: 22552265
Drug: R1663 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: R1663 (300 mg twice daily or 400 mg once daily for seven days)
Study: 11994054
Drug: entacapone 200
Normalized name: entacapone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: entacapone 200 mg four times daily
Study: 30808668
Drug: 21 mg
Normalized name: aspirin 421 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 mg nicotine patches
Study: 10048102
Drug: 7 mg
Normalized name: pectin 7 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 mg nicotine patches
Study: 7669957
Drug: Gallamine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallamine (40 mg intermittent bolus)
Study: 6119104
Drug: Conventional propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional propranolol (160 mg)
Study: 30810976
Drug: Fire-needle therapy
Normalized name: Fire Out
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fire-needle therapy once weekly for 4 weeks plus Oral Huoxue Jiedu Decoction and vaseline cream
Study: 30810976
Drug: Oral Huoxue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Huoxue Jiedu Decoction and vaseline cream
Study: 25732161
Drug: Paclitaxel plus
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel plus carboplatin (TC; paclitaxel 175 mg/m(2) over 3 hours and carboplatin AUC 5 mg/mL/min on day 1, repeated every 3 weeks)
Study: 25732161
Drug: Paclitaxel plus
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel plus cisplatin (TP; paclitaxel 135 mg/m(2) over 24 hours on day 1 and cisplatin 50 mg/m(2) on day 2, repeated every 3 weeks)
Study: 23632051
Drug: Intraarticular steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular steroid injections
Study: 21967070
Drug: Collagenase 0.58
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagenase 0.58 mg injections
Study: 17107257
Drug: Sertraline (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (25 mg/day)
Study: 17107257
Drug: Continuous dosing
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous dosing of sertraline
Study: 17107257
Drug: Symptom-onset dosing
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptom-onset dosing of sertraline
Study: 14612478
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine (100 microg/kg and 10 microg/kg per hour) for 7 days
Study: 6380335
Drug: Continuous glucose-insulin-potassium
Normalized name: glucose / potassium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous glucose-insulin-potassium (GIK) infusion for at least 4 hours after surgery
Study: 6380335
Drug: Continuous glucose-insulin-potassium
Normalized name: glucose / potassium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous glucose-insulin-potassium (GIK) infusion
Study: 6380335
Drug: Non-GIK treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-GIK treatment
Study: 20630306
Drug: NaOCl gel
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NaOCl gel
Study: 20630306
Drug: NaOCl solution
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NaOCl solution
Study: 30943227
Drug: Gummy candy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gummy candy containing 50 mg of ubiquinol, twice daily for 8 weeks
Study: 12645830
Drug: Salmeterol/fluticasone combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/fluticasone combination (SFC)
Study: 25523837
Drug: Dexmedetomidine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.5 μg·kg(‐1) iv (Group D)
Study: 20801464
Drug: Venlafaxine ER
Normalized name: Venlafaxine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine ER (75-300 mg/d)
Study: 24345717
Drug: Fluoxetine (20-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20-60 mg/d)
Study: 20801464
Drug: Venlafaxine ER
Normalized name: Venlafaxine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine ER and Fluoxetine
Study: 19841299
Drug: Iloprost 1
Normalized name: ILOPROST 100MCG/ML INJ,SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iloprost 1 ng kg(‐1) min(‐1) administered intravenously 30 to 90 minutes before and ending 4 hours after the procedure
Study: 19841299
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered intravenously 30 to 90 minutes before and ending 4 hours after the procedure
Study: 2487463
Drug: Single-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose oral amoxicillin
Study: 2487463
Drug: Single-dose TMP-SMX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose TMP-SMX (2 tablets DS)
Study: 1929311
Drug: Single-dose ofloxacin
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose ofloxacin (400 mg)
Study: 1105693
Drug: Intra-amniotic injection
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-amniotic injection of 2.5 mg of 15(S)-15-methyl-prostaglandin F2alpha
Study: 1105693
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of 15(S)-15-methyl-prostaglandin F2alpha (200 mug initially and 300 mug every third hour until 30 hrs or abortion)
Study: 31301741
Drug: Neuromuscular exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromuscular exercise (twice a week for 60 minutes over 6 months)
Study: 22241951
Drug: Insulin-stimulated endothelial
Normalized name: endothelial growth factor A, vascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-stimulated endothelial function in patients with systolic heart failure
Study: 22241951
Drug: Insulin-stimulated endothelial
Normalized name: endothelial growth factor A, vascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-stimulated endothelial function in healthy controls
Study: 22241951
Drug: Insulin-stimulated endothelial
Normalized name: endothelial growth factor A, vascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-stimulated endothelial function in patients with both heart failure and diabetes
Study: 17038057
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Siwak and orthodontic toothbrush
Study: 17038057
Drug: Siwak (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Siwak (in combination with orthodontic toothbrush)
Study: 1776352
Drug: Retrograde Venous
Normalized name: bushmaster venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrograde Venous Perfusion (RVP) treatment
Study: 1776352
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CG) treated with systemic i.v. infusions
Study: 1776352
Drug: RVP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: RVP treatment in patients with secondary osteomyelitis
Study: 1776352
Drug: RVP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: RVP treatment
Study: 6894606
Drug: Subcutaneous killed
Normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous killed poliovirus vaccine
Study: 6894606
Drug: Subcutaneous poliovirus
Normalized name: poliovirus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous poliovirus vaccination
Study: 6894606
Drug: Peroral liver
Normalized name: LIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peroral liver poliovirus vaccine
Study: 6894606
Drug: Peroral liver
Normalized name: LIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peroral liver poliovirus vaccine with subcutaneous killed Vibrio cholerae vaccine
Study: 26253887
Drug: Methylprednisolone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (1 g intraoperatively and 15 mg/kg for an additional 3 days)
Study: 22684738
Drug: Remifentanil Ce
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil Ce = 2 ng ml(‐1)
Study: 22684738
Drug: Remifentanil Ce
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil Ce = 4 ng ml(‐1)
Study: 17084395
Drug: hCG administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG administration during IVF cycles
Study: 17084395
Drug: Declining E(2)
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Declining E(2) levels after hCG administration
Study: 15692762
Drug: Doxorubicin 75
Normalized name: DOXOrubicin 75 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 75 mg/M2 q2 wks x 3 and docetaxel 40 mg/M2 weekly x 6
Study: 10599371
Drug: Tauredon (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tauredon (50 mg/week intramuscularly)
Study: 7818648
Drug: Bendrofluazide 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendrofluazide 1.25 mg
Study: 7818648
Drug: Bendrofluazide 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendrofluazide 5.0 mg